Dai Maruyama

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 203 publications

Overview

Overview

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 03, 2026

Histiocytic sarcoma with a common clonal origin emerged after 33 years from B-cell precursor acute lymphoblastic leukemia.

Histiocytic sarcoma with a common clonal origin emerged after 33 years from B-cell precursor acute lymphoblastic leukemia.

Journal: Journal of clinical and experimental hematopathology : JCEH
Published: June 28, 2026

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine
Published: June 15, 2026

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

Journal: International journal of hematology
Published: March 18, 2026

Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma.

Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma.

Journal: Cancers
Published: February 16, 2026

Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Journal: International journal of clinical oncology
Published: January 15, 2026

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Journal: Annals of hematology
Published: January 13, 2026

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

Journal: International journal of clinical oncology
Published: January 06, 2026

Novel agents and therapeutic advances in T cell lymphoma.

Novel agents and therapeutic advances in T cell lymphoma.

Journal: International journal of hematology
Published: December 16, 2025

Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicity.

Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicity.

Journal: Leukemia
Published: December 15, 2025

Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma.

Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma.

Journal: International journal of clinical oncology
Published: October 29, 2025

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Journal: Lancet (London, England)
Published: October 24, 2025
Showing 1-12 of 203

Last Updated: 09/26/2026